Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5013 - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)


28 Sep 2019


Poster Display session 1


Tumour Site



Maud Pedrono


Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283


M. Pedrono1, O. Mir2, L. Chaltiel3, M. Brahmi4, A. Italiano5, G. Decanter6, P. Boudou Rouquette7, M. Ropars8, E. Bompas9, N. Firmin10, N. Isambert11, T. VALENTIN12, F. Duffaud13, J. Gantzer14, A. Thyss15, C. Guillemet16, J. Blay4, A. Le Cesne2, C.M. Chevreau12, C. Perrin1

Author affiliations

  • 1 Medical Oncology, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 2 Département De Médecine Oncologique, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 3 Biostatistics Unit, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole,, 31000 - Toulouse/FR
  • 4 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 5 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 6 Surgery, Centre Oscar Lambret, 59000 - lille/FR
  • 7 Medical Oncology, Hôpital Cochin - APHP, 75014 - Paris/FR
  • 8 Orthopedic Surgery, CHU Pontchaillou, 35000 - Rennes/FR
  • 9 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 10 Medical Oncology, Institut du Cancer de Montpellier, 34298 - Montpellier/FR
  • 11 Department Of Medical Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 12 Medical Oncology, IUCT-Oncopôle Institut Claudius Regaud, 31059 - Toulouse/FR
  • 13 Medical Oncology, CHU La Timone Adultes, 13385 - Marseille/FR
  • 14 Medical Oncology, C.H.U. Strasbourg-Nouvel Hopital Civil, 67000 - Strasbourg/FR
  • 15 Medical Oncology, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 16 Medical Oncology, Centre Henri Becquerel, 76038 - Rouen/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5013


Epithelioid sarcoma (ES) is a rare soft-tissue sarcoma (STS) (1%). Few recent studies describe pathological and clinical characteristics of ES. Little is known about management and outcomes of patients with localized diseases. The objectives are to study tumor characteristics and clinical management of ES patients with local and locally-advanced disease.


This is a retrospective study from the nation-wide French sarcoma network (NetSarc). From 2000 to 2016, patients with confirmed ES by expert pathologists, and with a localized disease were included. R2 were excluded.


A total of 98 patients were analysed from 13 centres. Median age was 38 years (range 9-90) with male predominance (56%). The median size was 4 cm (0.3-72). Most common location was distal upper limb (40%). Pre-surgical biopsy was performed in 46% of patients. R0 resection was obtained for 64 patients (79%), R1 for 17 patients (21%). Margins revision surgery has been performed in 51% of patients. Limb-sparing was possible in 73% patients and amputation in 27%. Twenty-five patients (26%) received neoadjuvant treatments mainly chemotherapy with doxorubin-based regimen or isolated limb perfusion in 8 patients (10%). After surgery, 40 patients (43%) received adjuvant treatment, mainly radiotherapy (93%) and 20% received chemotherapy. After a median follow-up of 66.2 months (IC 95 48.4-74.7), 52% patients relapsed : locoregional relapse for 25 patients (52%), distant metastases for 35 patients (75%). The median disease-free-survival (DFS) was 54.5 months (IC95 33.7-105.6). Five-year overall survival (OS) rate was 71% (IC95 59-80). By univariate analyses, locally advanced disease and size larger than 5 cm were identified as a poor-prognosis factors for DFS and OS. R1 surgical margins were prognostic for OS. Proximal location, necrosis, mitosis index had no significant prognostic impact.


ES have a high rate of recurrence, particularly as locoregional relapse. Locally advanced disease, size larger than 5 cm, R1 surgical margins were identified as a poor-prognosis factors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Perrin Christophe.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.